Several brokerages have updated their recommendations and price targets on shares of Acrivon Therapeutics (NASDAQ: ACRV) in the last few weeks:
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc.. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $17.00 price target on the stock.
- 12/11/2022 – Acrivon Therapeutics is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Acrivon Therapeutics Stock Up 0.1 %
NASDAQ:ACRV opened at $11.51 on Wednesday. Acrivon Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $20.70.
Insider Activity at Acrivon Therapeutics
In related news, major shareholder Ltd Chione purchased 400,000 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the insider now owns 3,856,597 shares in the company, valued at approximately $48,207,462.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 3,389,500 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the completion of the acquisition, the director now owns 4,384,206 shares in the company, valued at approximately $54,802,575. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ltd Chione acquired 400,000 shares of the business's stock in a transaction dated Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider now directly owns 3,856,597 shares of the company's stock, valued at $48,207,462.50. The disclosure for this purchase can be found here.
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Featured Stories
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
Receive News & Ratings for Acrivon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.